Molecular marker and application thereof in detection of vascular immunoblastic T cell lymphoma

Abstract

The invention discloses a molecular marker and an application thereof in detection of vascular immunoblastic T cell lymphoma, and belongs to the technical field related to blood disease detection. According to the application, a combination of multiple markers disclosed by the invention is applied to flow cytometry detection of vascular immunoblastic T cell lymphoma and/or monitoring of minimal residual focuses. The molecular marker disclosed by the invention can be widely applied to living cell samples such as bone marrow, peripheral blood, lymph nodes, puncture objects, skin tissues, pleural effusion, peritoneal effusion and the like of a patient, the combination of various markers is effectively arranged, abnormal cells of AITL can be quickly screened out in an early stage, the sensitivity and specificity to tissue samples reach 100%, the use amount of cells is small, and operation is rapid, simple and convenient. Meanwhile, for a patient subjected to chimeric antigen receptor T cell treatment, the composition disclosed by the invention can also be used for evaluating the immunofluorescence intensity of an antigen target spot, the immunofluorescence intensity is an indispensable part in cell treatment, and subsequent residue monitoring is not influenced by treatment.

Description

technical field [0001] The invention relates to a useful marker for disease diagnosis and belongs to the technical field of blood disease detection, in particular to a molecular marker and its application in detecting angioimmunoblastic T-cell lymphoma. Background technique [0002] Angioimmunoblastic T-cell lymphoma (AITL) is a kind of peripheral T-cell lymphoma, accounting for about 20% of peripheral T-cell lymphomas. Its long-term prognosis is poor, and the 5-year survival rate is about 30-40%. Pathologically, the most typical changes are destruction of follicular structure, high endothelial vein hyperplasia and dendritic cell hyperplasia. However, because the proportion of abnormal cells in AITL is often very low, and the background cells are abundant, most of them are a large number of normal T lymphocytes, B lymphocytes, immunoblasts, eosinophils or scattered RS cells, only through pathology and immunohistochemistry , Sometimes it is difficult to distinguish AITL from...

AI Technical Summary

Problems solved by technology

[0006] In summary, the existing multi-parameter flow cytometry has the following problems: 1. It is not suitable for patients without pan-T marker expression loss, and such patients often cannot find abnormal cells by conventional gating methods

2. If the abnormal cells only express CD3 on the membrane with a slightly weaker expression and the expression of CD7 is normal, it is often easy to miss the diagnosis for inexperienced personnel

3. The current primary screening method cannot judge the clonality of T lymphocytes, and cannot identify benign and malignant CD4+CD7- cell populations

4. Using TCR Vβ for T cell clonality identification requires a large amount of samples, high cost, and time-consuming and laborious operation

5. For punctures or bone marrow samples with a small amount of cells, it is impossible to determine the type of tumor cells at one time

6. If the abnormal cells need to use multiple pan-T markers to set the gate, the cost of adding it later will be higher

7. If the tumor cells cannot be targeted, the average fluorescence intensity of the antigen cannot be evaluated, which will affect the follow-up treatment

Images